HARVARD BIOSCIENCE INC
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||
| (Unaudited, in thousands, except per share data) | ||
| Three Months Ended March 31, | ||
| 2026 | 2025 | |
| Revenues | $20,755 | $21,774 |
| Cost of revenues | 8,511 | 9,590 |
| Gross profit | 12,244 | 12,184 |
| Sales and marketing expenses | 5,335 | 4,971 |
| General and administrative expenses | 4,702 | 5,185 |
| Research and development expenses | 2,326 | 2,321 |
| Amortization of acquired intangible assets | 820 | 1,160 |
| Goodwill impairment - Note 5 | - | 47,951 |
| Other operating expenses - Note 2 | 235 | 264 |
| Total operating expenses | 13,418 | 61,852 |
| Operating loss | (1,174) | (49,668) |
| Other expense: | ||
| Interest expense | (1,728) | (933) |
| Other expense, net | (405) | (193) |
| Total other expense | (2,133) | (1,126) |
| Loss before income taxes | (3,307) | (50,794) |
| Income tax expense (benefit) | 117 | (454) |
| Net loss | $(3,424) | $(50,340) |
| Loss per share: | ||
| Basic and diluted loss per share * | $(0.77) | $(11.42) |
| Weighted-average common shares: | ||
| Basic and diluted * | 4,473 | 4,410 |
| * | Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13,2026. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.